<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04463251</url>
  </required_header>
  <id_info>
    <org_study_id>CL04018075</org_study_id>
    <nct_id>NCT04463251</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction</brief_title>
  <official_title>International, Double Blind, Randomized, Placebo-controlled Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R-Pharm Overseas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cromos Pharma LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>DM 365, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keystat, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>R-Pharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to evaluate the effect of single administration of RPH-104 at 80 mg&#xD;
      and 160 mg on parameters of systemic inflammation and outcomes of the disease in subjects&#xD;
      with ST-segment elevation myocardial infarction (STEMI)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      146 male and female subjects aged from 18 years old (inclusive) hospitalized with STEMI will&#xD;
      be enrolled in the study. 102 subjects will be randomized, 34 subjects per group.&#xD;
&#xD;
      After signing informed consent, the investigator will assess the subject's eligibility for&#xD;
      the study. The screening will be made on Day 1 of the study.&#xD;
&#xD;
      Subjects will be randomly assigned to 1 of 3 treatment groups (in a 1:1:1 ratio) for single&#xD;
      subcutaneous administration of RPH-104 80 mg, RPH-104 160 mg or placebo.&#xD;
&#xD;
      Screening, randomization and administration of the study products will be made on the same&#xD;
      (first) study day.&#xD;
&#xD;
      Follow-up period after administration of the study products will last for 4 weeks and will&#xD;
      include follow-up after administration of the study product (Day 1), Visit 2 (Day 3), Visit 3&#xD;
      (Day 14) and Visit 4 (Day 28±1). The following will be performed during this period: the&#xD;
      subject's condition monitoring, laboratory and instrumental examination.&#xD;
&#xD;
      Additional clinical follow-up will last for 12 months after the study product administration&#xD;
      and will include Visit 5 (Month 6 ±2 weeks) and Visit 6 (Month 12 ±2 weeks). During this&#xD;
      period, the subject's condition will be monitored and laboratory and instrumental examination&#xD;
      will be performed.&#xD;
&#xD;
      The end of clinical part of the study will be the date of the last visit of the last subject&#xD;
      within additional 12-month clinical follow-up.&#xD;
&#xD;
      The study is planned to be conducted in Russian Federation and USA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 14, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hsCRP area under curve (AUC) from baseline until Day 14</measure>
    <time_frame>Day 1 , Day 3 and Day 14</time_frame>
    <description>hsCRP area under curve (AUC) from baseline (Day 1) until Day 14</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hsCRP area under curve (AUC) from baseline until Day 28</measure>
    <time_frame>From Day 1 until Day 28</time_frame>
    <description>hsCRP area under curve (AUC) from baseline (Day 1) until Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of fatal outcomes (cardiac and non-cardiac), hospitalizations (due to heart failure (HF) and other cardiac reasons not associated with HF or due to non-cardiac reasons) during 12-month follow-up period</measure>
    <time_frame>From Day 1 until Day 365</time_frame>
    <description>Rate of fatal outcomes (cardiac and non-cardiac), hospitalizations (due to heart failure (HF) and other cardiac reasons not associated with HF or due to non-cardiac reasons) during 12-month follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of new cases of HF during 12-month follow-up period</measure>
    <time_frame>From Day 1 until Day 365</time_frame>
    <description>Frequency of new cases of HF (defined as hospitalization due to HF or necessity in a loop diuretic administration intravenously or oral dose doubling in the relevant clinical facilities) during 12-month follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in levels of brain natriuretic peptide (BNP, NT-proBNP) during 12-month follow-up period compared to baseline</measure>
    <time_frame>From Day 1 until Day 365</time_frame>
    <description>Changes in levels of brain natriuretic peptide (BNP, NT-proBNP) during 12-month follow-up period compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in structural and functional echocardiographic parameters : left ventricular (LV) and right ventricular dimensions after 12 months compared to baseline</measure>
    <time_frame>From Day 1 Until Day 365</time_frame>
    <description>Changes in structural and functional echocardiographic parameters : left ventricular (LV) and right ventricular dimensions after 12 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in structural and functional echocardiographic parameters : Left ventricular muscle mass index (LVMMI) after 12 months compared to baseline</measure>
    <time_frame>From Day 1 Until Day 365</time_frame>
    <description>Changes in structural and functional echocardiographic parameters : Left ventricular muscle mass index (LVMMI) after 12 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in structural and functional echocardiographic parameters : LV systolic function after 12 months compared to baseline</measure>
    <time_frame>From Day 1 Until Day 365</time_frame>
    <description>Changes in structural and functional echocardiographic parameters :LV systolic function after 12 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in structural and functional echocardiographic parameters : LV diastolic function after 12 months compared to baseline</measure>
    <time_frame>From Day 1 Until Day 365</time_frame>
    <description>Changes in structural and functional echocardiographic parameters :LV diastolic function after 12 months compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Acute ST Segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>RPH-104 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will receive subcutaneous single injection of 2 mL (80 mg) of RPH-104 and 2 mL of placebo on different administration sites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPH-104 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will receive subcutaneous single injection of 2 mL (80 mg) of RPH-104 and 2 mL of (80 mg) of RPH-104 on different administration sites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subjects will receive subcutaneous single injection of 2 mL of placebo and 2 mL of placebo on different administration sites</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RPH-104 80 mg</intervention_name>
    <description>solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial</description>
    <arm_group_label>RPH-104 160 mg</arm_group_label>
    <arm_group_label>RPH-104 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4-mL transparent glass vial</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>RPH-104 80 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who gave voluntary written Informed consent to participate in the study and&#xD;
             to follow all Protocol procedures.&#xD;
&#xD;
          -  STEMI diagnosis defined as chest pain or its equivalent with debut no more than 12&#xD;
             hours before randomization and ECG findings evidencing ST elevation (&gt;1 mm) in two or&#xD;
             more consecutive leads or acute left bunch branch block (LBBB) according the&#xD;
             investigator's judgement.&#xD;
&#xD;
          -  Percutaneous coronary intervention (PCI) with stenting was performed within no more&#xD;
             than 12 hours after onset of chest pain or its equivalent before randomization.&#xD;
&#xD;
          -  Consent of female subjects with childbearing potential defined as all female subjects&#xD;
             with physiological potential to conceive, to use highly effective contraceptive&#xD;
             methods throughout the study starting from screening (signing Informed Consent Form)&#xD;
             and negative pregnancy test.&#xD;
&#xD;
        Highly effective contraceptive methods include combination of two of the following methods&#xD;
        (a+b or a+c or b+c):&#xD;
&#xD;
          1. oral, injection or implanted hormonal contraceptives; in case of oral contraceptives,&#xD;
             the female subjects should administer the same product for at least 3 months prior to&#xD;
             the study therapy;&#xD;
&#xD;
          2. intrauterine device or contraceptive system;&#xD;
&#xD;
          3. barrier methods: condom or occlusive cap (diaphragm or cervical cap / vaginal fornix&#xD;
             cap) with spermicidal foam/gel/film/cream/vaginal suppository&#xD;
&#xD;
               -  Ability and willingness of the subject, according to the reasonable&#xD;
                  investigator's judgment, to attend the study site at all scheduled visits,&#xD;
                  undergo the study procedures and follow the protocol requirements including&#xD;
                  subcutaneous injections by qualified site personnel.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to test product (RPH-104) and/or its ingredients/excipients.&#xD;
&#xD;
          -  Pregnancy and breastfeeding.&#xD;
&#xD;
          -  Verified chronic heart failure (The American Heart Association / The American College&#xD;
             of Cardiology (AHA/ACC) A-D class, New York Heart Association (NYHA) Functional class&#xD;
             (FC) I-IV)&#xD;
&#xD;
          -  Pre-existing decompensated heart defects.&#xD;
&#xD;
          -  History of STEMI&#xD;
&#xD;
          -  Complications of acute myocardial infarction in the form of acute left ventricular&#xD;
             failure and cardiogenic shock defined as stable blood pressure decrease (SBP&lt;90 mm Hg)&#xD;
             associated with signs of hypoperfusion as well as cases when inotropic and/or&#xD;
             mechanical support is required to maintain SBP; and / or unstable hemodynamics.&#xD;
&#xD;
          -  Active infections (acute or chronic); active tuberculosis&#xD;
&#xD;
          -  Recent (less than 5 half-life periods) or current administration of agents with an&#xD;
             immunosuppressant mechanism of action, including, but not limited to, high doses of&#xD;
             glucocorticoids (&gt; 1 mg/kg of methylprednisolone equivalent),Tumour Necrosis Factor&#xD;
             (TNF) alpha blockers, Interleukin-1 (IL-1) and other biological drugs, cyclosporine&#xD;
             and other immunosuppressants. NSAIDs are allowed.&#xD;
&#xD;
          -  Immunization with live vaccines within 90 days prior to the study product&#xD;
             administration.&#xD;
&#xD;
          -  Chronic systemic autoimmune or autoinflammatory diseases&#xD;
&#xD;
          -  Suspected necessity in cardiosurgery&#xD;
&#xD;
          -  Oncology (or diagnosis of oncology within the last 5 years).&#xD;
&#xD;
          -  History of organ transplantation or necessity in transplantation at the screening&#xD;
             initiation or scheduled transplantation during the study.&#xD;
&#xD;
          -  Neutropenia (absolute neutrophil count &lt;1800/mm3).&#xD;
&#xD;
          -  Participation in another clinical study within the previous 3 months prior to&#xD;
             Screening visit.&#xD;
&#xD;
          -  Other medical or mental conditions or abnormal laboratory findings which may increase&#xD;
             the risk for the subject associated with the study participation or administration of&#xD;
             the study products or which may affect interpretation of the study results and,&#xD;
             according to the investigator, render the subject ineligible for the study.&#xD;
&#xD;
          -  The subjects working at the study site or subjects working for Sponsor directly&#xD;
             involved in this clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Lavrovsky</last_name>
    <role>Study Director</role>
    <affiliation>R-Pharm Overseas, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UF Health Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Franchi</last_name>
      <phone>904-327-2741</phone>
      <email>francesco.franchi@jax.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sinai Center of Thrombosis Research and Drug Development</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Gurbel</last_name>
      <phone>410-367-2590</phone>
      <email>pgurbel@lifebridgehealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Cremer</last_name>
      <phone>216-444-6765</phone>
      <email>cremerp@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-5051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Abbate, MD</last_name>
      <phone>804-828-0513</phone>
      <email>antonio.abbate@vcuhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional State budgetary healthcare institution &quot; Altai regional cardiological dispensary&quot;</name>
      <address>
        <city>Barnaul</city>
        <zip>656055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexey I. Duda</last_name>
      <phone>+7 913 270 81 08</phone>
      <email>alexeyduda@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare of Moscow &quot;City Clinical Hospital №64&quot; of the Moscow Department of Health</name>
      <address>
        <city>Moscow</city>
        <zip>117292</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imad A. Meray</last_name>
      <phone>+7 916 182 22 30</phone>
      <email>imadmerai@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Institution of Healthcare in Moscow &quot;City Clinical Hospital № 51 Moscow Health Department&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>121309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dmitry V. Privalov</last_name>
      <phone>+7 926 214 64 04</phone>
      <email>d.v.priv@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal State Institution &quot;Russian Cardiology Research and Production Complex&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dmitry V. Pevzner</last_name>
      <phone>+7 916 696 32 92</phone>
      <email>pevsner@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare &quot;City Clinical Hospital #52&quot;, Moscow City Healthcare Department</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgy N. Abrolishvili</last_name>
      <phone>+7 926 529 71 33</phone>
      <email>geodoc@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moscow State Clinical Hospital named after V.V. Veresaev</name>
      <address>
        <city>Moscow</city>
        <zip>127644</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shogenov S. Zaur</last_name>
      <phone>+7 985 769 28 96</phone>
      <email>zaurshogenov@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Autonomous institution of healthcare of the Perm region &quot;City clinical hospital № 4&quot;</name>
      <address>
        <city>Perm</city>
        <zip>2614107</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleg M. Lapin</last_name>
      <phone>+7 902 471 36 59</phone>
      <email>heparin@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State budgetary educational institution of higher professional education &quot;North-Western State Medical University named after I.I. Mechnikov&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana A. Boldueva</last_name>
      <phone>+7 921 931 74 49</phone>
      <email>svetlanaboldueva@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare of Saint-Petersburg &quot;Hospital for war veterans&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>193079</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir O. Konstantinov</last_name>
      <phone>+7 921 948 72 31</phone>
      <email>atherosclerosis@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National medical research center named after V. A. Almazov</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexei N. Yakovlev</last_name>
      <phone>+7 905 251 64 65</phone>
      <email>alex.yakovlev@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Budgetary Institution of Healthcare &quot;City Hospital №40&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alina S. Agafyina</last_name>
      <phone>+7 921 58378 08</phone>
      <email>a.agafina@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State budgetary educational institution of higher professional education &quot;North-Western State Medical University named after I.I. Mechnikov&quot;, Pokrovskaya Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergey A. Sayganov</last_name>
      <phone>+7 921 948 40 93</phone>
      <email>sergey.sayganov@mail.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 3, 2020</study_first_submitted>
  <study_first_submitted_qc>July 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2020</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>Cardiovascular diseases</keyword>
  <keyword>CVD</keyword>
  <keyword>Coronary heart disease</keyword>
  <keyword>CHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

